Company intelligence / Profile preview

Ovizio Imaging Systems

Brussels, Belgium

Ownership: Private
Development stage: Other

Overview

Ovizio Imaging Systems develops and commercializes label-free cell analyzers for bioprocessing, with a focus on cell and gene therapy and vaccine production; its iLine F PRO platform enables real-time, non-invasive cell culture monitoring and analysis, supporting automation and increased quality; in 2023, the company was acquired by ChemoMetec for EUR 2.83 million and has respected customers in pharma/biotech, generating EUR 1.4 million in revenue.

Modalities: Device (cell counter/microscopy platform)
Industry: Pathology

Partnerships

Merck KGaA Life Science (commercial promotion partnership for iLine F PRO in Europe and North America, cell & gene therapy space)

Beyond the preview

Go deeper on Ovizio Imaging Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ovizio Imaging Systems.

Explore the full profile